On September 27th, the US stock market of Bristol Myers Squibb rose more than 5% before trading, as US regulatory authorities approved its Cobenfy for the treatment of schizophrenia, the first drug a ...

According to the AI news, the US stock market of Bristol Myers Squibb rose more than 5% before trading. The US regulatory authorities approved its Cobenfy for the treatment of schizophrenia, which is ...